Immuno-cardio-oncology: Killing two birds with one stone?

Linthout, Sophie Van; Volk, Hans‐Dieter

doi:10.3389/fimmu.2022.1018772

Cited by 4 publications

(1 citation statement)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, NLRP3 inflammasome has a pivotal role in a broad spectrum of diseases, including cardiac diseases [11] and cancer [9]. In cancer, NLRP3 and IL-1β drive cancer progression involving tumorigenesis promotion, angiogenesis, immunosuppression, and metastasis [12,13]. Colchicine (COL) (PubChem CID: 6167) https://pubchem.ncbi.nlm.nih.gov/compound/616 7 originally isolated from Colchicum autumnale, is a tricyclic alkaloid drug [14] clinically used for inflammatory diseases treatment as the gouty arthritis and familial Mediterranean fever (FMF) [15].…”

Section: Introductionmentioning

confidence: 99%

Colchicine Enhances the Apoptotic, Anti-tumor Efficacy, Survival of Doxorubicin and Lowers Associated Toxicity in an Ehrlich Ascites Cancer Mouse Model

El-Tabakh,

Wasfey,

Linthout

et al. 2023

Archives of Pharmaceutical Sciences Ain Shams University

View full text Add to dashboard Cite

Doxorubicin (DOX) is an effective chemotherapeutic drug but induces serious adverse effects. The antiinflammatory drug colchicine (COL) was found to inhibit inflammasome activity involved in DOX side effects. The purpose of this research is to investigate COL impact when being added to DOX if decreases side effects or enhances its anti-tumor efficacy. To this end, we used Ehrlich ascitic carcinoma (EAC)-bearing CD1 female mice and treated them with high and low doses of DOX (DOX high and DOX low ) in the presence or absence of COL. Mice were inoculated intraperitoneally with 0.25 × 10 6 EAC-cells/mouse and then treated with DOX high (2 mg/kg), DOX low (1 mg/kg), COL (5 µmol/kg), DOX high /COL and DOX low /COL. On day 8 of tumor injection, 50% of the mice were sacrificed to evaluate tumor volume, total tumor cell count, EAC cell apoptosis, cell cycle, hematological, and biochemical parameters, including liver and kidney function tests, oxidative stress (OS) markers, C-reactive protein (CRP), and interleukin 1-beta (IL-1β). The remaining 50% of mice were left to determine the survival of the groups. Co-treatment of COL with DOX high or DOX low enhanced the overall antitumor effect of DOX as evidenced by an enhancement in the tumor parameters, an increase in EAC cell apoptosis, and induction of cell cycle arrest. Additionally, their co-treatment ameliorated DOX adverse effects as evidenced by an improvement in the measured markers. Conclusion: Combination of COL with DOX high or DOX low enhanced the antitumor effect and decreased the adverse effects. This study opens a new avenue to their use in the clinical setting.

show abstract